1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/22882
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDhiman, Kunal-
dc.contributor.authorGupta, Veer Bala-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorEratne, Dhamidhu-
dc.contributor.authorGraham, Petra L-
dc.contributor.authorFowler, Christopher-
dc.contributor.authorBourgeat, Pierrick-
dc.contributor.authorLi, Qiao-Xin-
dc.contributor.authorCollins, Steven-
dc.contributor.authorBush, Ashley I-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorAmes, David-
dc.contributor.authorHone, Eugene-
dc.contributor.authorBlennow, Kaj-
dc.contributor.authorZetterberg, Henrik-
dc.contributor.authorMartins, Ralph N-
dc.date2020-02-27-
dc.date.accessioned2020-03-31T03:15:24Z-
dc.date.available2020-03-31T03:15:24Z-
dc.date.issued2020-02-27-
dc.identifier.citationAlzheimer's & dementia (Amsterdam, Netherlands) 2020; 12(1): e12005en
dc.identifier.issn2352-8729-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/22882-
dc.description.abstractThis study assessed the utility of cerebrospinal fluid (CSF) neurofilament light (NfL) in Alzheimer's disease (AD) diagnosis, its association with amyloid and tau pathology, as well as its potential to predict brain atrophy, cognition, and amyloid accumulation. CSF NfL concentration was measured in 221 participants from the Australian Imaging, Biomarkers & Lifestyle Flagship Study of Ageing (AIBL). CSF NfL levels as well as NfL/amyloid β (Aβ42) were significantly elevated in AD compared to healthy controls (HC; P < .001), and in mild cognitive impairment (MCI) compared to HC (P = .008 NfL; P < .001 NfL/Aβ42). CSF NfL and NfL/Aβ42 differentiated AD from HC with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.84 and 0.90, respectively. CSF NfL and NfL/Aβ42 predicted cortical amyloid load, brain atrophy, and cognition. CSF NfL is a biomarker of neurodegeneration, correlating with cognitive impairment and brain neuropathology.en
dc.language.isoeng-
dc.subjectELISAen
dc.subjectamyloiden
dc.subjectbiomarkeren
dc.subjectdementiaen
dc.subjectdiagnosisen
dc.subjectneurodegenerationen
dc.subjectneurofilamentsen
dc.titleCerebrospinal fluid neurofilament light concentration predicts brain atrophy and cognition in Alzheimer's disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleAlzheimer's & dementia (Amsterdam, Netherlands)en
dc.identifier.affiliationCentre for Economic Impacts of Genomic Medicine (GenIMPACT) Macquarie University Sydney NSW Australiaen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old age St. George's Hospital The University of Melbourne Australiaen
dc.identifier.affiliationKaRa Institute of Neurological Diseases Sydney NSW Australiaen
dc.identifier.affiliationCentre of Excellence in Alzheimer's Disease Research and Care School of Medical and Health Sciences Edith Cowan University Joondalup WA Australiaen
dc.identifier.affiliationCo-operative Research Centre for Mental Health Carlton Victoria Australiaen
dc.identifier.affiliationAustralian Alzheimer's Research Foundation Ralph and Patricia Sarich Neuroscience Research Institute Nedlands WA Australiaen
dc.identifier.affiliationDepartment of Biomedical Sciences Macquarie University Sydney NSW Australiaen
dc.identifier.affiliationSchool of Psychiatry and Clinical Neurosciences University of Western Australia Perth WA Australiaen
dc.identifier.affiliationDepartment of Psychiatry and Neurochemistry Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Mölndal Swedenen
dc.identifier.affiliationClinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Swedenen
dc.identifier.affiliationDepartment of Neurodegenerative Disease UCL Queen Square Institute of Neurology Queen Square London UKen
dc.identifier.affiliationUK Dementia Research Institute at UCL London UKen
dc.identifier.affiliationClinical Neurochemistry Laboratory Sahlgrenska University Hospital Mölndal Swedenen
dc.identifier.affiliationNational Ageing Research Institute Parkville Victoria Australiaen
dc.identifier.affiliationDepartment of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationFlorey Institute of Neuroscience and Mental Health Parkville Victoria Australiaen
dc.identifier.affiliationMelbourne Neuropsychiatry Centre University of Melbourne and NorthWestern Mental Health Parkville Victoria Australiaen
dc.identifier.affiliationCSIRO Health and Biosecurity Brisbane Australiaen
dc.identifier.affiliationSchool of Medicine Deakin University Victoria Australiaen
dc.identifier.affiliationDepartment of Medicine University of Melbourne Melbourne Victoria Australiaen
dc.identifier.doi10.1002/dad2.12005en
dc.type.contentTexten
dc.identifier.orcid0000-0002-5832-9875en
dc.identifier.pubmedid32211500-
dc.type.austinJournal Article-
local.name.researcherMasters, Colin L
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

58
checked on Dec 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.